DEBIOPHARM GROUP
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. They develop their products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.
DEBIOPHARM GROUP
Industry:
Biotechnology Medical Medical Device Pharmaceutical
Founded:
1979-01-01
Address:
Lausanne, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.debiopharm.com
Total Employee:
251+
Status:
Active
Contact:
+41213210111
Total Funding:
4.7 M USD
Technology used in webpage:
Apple Mobile Web Clips Icon Amazon ASP.NET IIS Amazon Virginia Region Java EE Lorem Ipsum WordPress 5.8 Apple Whitelist IIS 7
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Nanoform Therapeutics
Nanoform Therapeutics develops new generation of Bio-Pharmaceutical developmental or marketed drugs.
Current Employees Featured
Thierry Mauvernay President & Delegate of the Board @ Debiopharm Group
President & Delegate of the Board
Sophie Genecand Director, Real Estate department, Debiopharm Investment S.A. @ Debiopharm Group
Director, Real Estate department, Debiopharm Investment S.A.
ANGELA ZUBEL Chief Development Officer @ Debiopharm Group
Chief Development Officer
2019-02-01
Bertrand Ducrey CEO @ Debiopharm Group
CEO
2012-01-01
Raymond Zaugg Director, Financial department, Debiopharm Investment S.A @ Debiopharm Group
Director, Financial department, Debiopharm Investment S.A
Riccardo Nisato Licensing and Grants Associate Manager @ Debiopharm Group
Licensing and Grants Associate Manager
2021-04-01
Alexandra Le Coz Sanchez Associate Director, Private Equity Department, Debiopharm Investment S.A. @ Debiopharm Group
Associate Director, Private Equity Department, Debiopharm Investment S.A.
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-02-11 | Affinium Pharmaceuticals | Affinium Pharmaceuticals acquired by Debiopharm Group | N/A |
Investors List
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-01-09 | Novadiscovery | Debiopharm Group investment in Series A - Novadiscovery | 5 M EUR |
| 2019-11-10 | Little Green House | Debiopharm Group investment in Corporate Round - Little Green House | N/A |
| 2016-10-26 | Coorpacademy | Debiopharm Group investment in Series B - Coorpacademy | 10 M EUR |
| 2015-04-03 | Immunexpress | Debiopharm Group investment in Debt Financing - Immunexpress | 40 M USD |
| 2014-11-17 | Coorpacademy | Debiopharm Group investment in Series A - Coorpacademy | 3.2 M EUR |
| 2014-05-05 | Immunexpress | Debiopharm Group investment in Series B - Immunexpress | 18 M USD |
| 2014-03-05 | Immunexpress | Debiopharm Group investment in Funding Round - Immunexpress | 6 M USD |
| 2013-12-03 | BPA Solutions | Debiopharm Group investment in Funding Round - BPA Solutions | N/A |
| 2013-09-06 | Skioo | Debiopharm Group investment in Venture Round - Skioo | N/A |
| 2013-05-22 | Urturn | Debiopharm Group investment in Series A - Urturn | 13.4 M USD |
Newest Events participated
Participated in Swiss Startup Day
on 2015-10-21 as sponsor
Official Site Inspections
http://www.debiopharm.com Semrush global rank: 4.77 M Semrush visits lastest month: 1.93 K
- Host name: havps24.iron.bsa.oriented.ch
- IP address: 185.15.230.34
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
Debiopharm.com lookup results from whois.networksolutions.com server:
- Domain created: 26th-Jan-1999
- Domain updated: 27th-Feb-2025
- Domain expires: 26th-Jan-2026 0 Years, 304 Days left
- Website age: 26 Years, 61 Days
- Registrar Domain ID: 3232095_DOMAIN_COM-VRSN
- Registrar Url: http://networksolutions.com
- Registrar WHOIS Server: whois.networksolutions.com
- Registrar Abuse Contact Email: domain.operations@web.com
- Registrar Abuse Contact Phone: +1.8777228662
- Name server:
- NS1-01.AZURE-DNS.COM
- NS2-01.AZURE-DNS.NET
- NS3-01.AZURE-DNS.ORG
- NS4-01.AZURE-DNS.INFO
More informations about "Debiopharm Group"
Debiopharm - Wikipedia
Debiopharm is known for the development of triptorelin and oxaliplatin, two drugs that became standards of care for the treatment of various types of cancer and are listed on the World Health Organization's List of Essential Medicines. • Triptorelin is a gonadotropin-releasing hormone agonist (GnRH agonist) approved for several indications, including prostate cancer and endometriosis, under the names Decapeptyl, Neo Dec…See details»
Debiopharm Group - Crunchbase Company Profile
Debiopharm Group may be growing as it has provided additional funding to MedaSystems, which indicates an increase in investment activities. This financial support is aimed at accelerating global access to pre-approval treatment, …See details»
Leadership Team - Debiopharm
Debiopharm, with 15 ongoing drug research programs, has developed two blockbuster therapies for cancer patients, oxaliplatin and triptorelin, along with a potential 3rd Head & Neck Cancer …See details»
Drug Development - Debiopharm
Debiopharm is an innovation-focused, Swiss biopharmaceutical company that aims to develop novel therapies to target high unmet medical needs in oncology and infectious diseases. We establish partnerships with academic, biotech, …See details»
Debiopharm Group - Funding, Financials, Valuation & Investors
Debiopharm Group is a biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug. Search Crunchbase. ... How much funding has this …See details»
Debiopharm International SA - Swiss Biotech
Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to improve patient outcomes and quality of life in oncology and bacterial infections. Our main activities include drug …See details»
Debiopharm - LinkedIn
Debiopharm | 35,122 followers on LinkedIn. we develop for patients | Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for ...See details»
Debiopharm | VentureRadar
Debiopharm is an independent biopharmaceutical company dedicated to developing tomorrow’s standard of care for cancer and infectious diseases, while enhancing patient quality of life. The …See details»
Debiopharm - Swiss Biotech
Family-owned Debiopharm from Lausanne, identifies high-potential compounds in oncology and for the treatment of bacterial infections. They are tested in clinical development and licensed to …See details»
Debiopharm Group - Contacts, Employees, Board Members
Debiopharm Group has 7 current employee profiles, including President & Delegate of the Board Thierry Mauvernay. Contacts. Edit Contacts Section. Job Department. Protected Content. …See details»
Our commitment to governance - Debiopharm
Keeping an agile structure to ensure continuity, operating with excellence to pursue our impactful objectives. Family shareholding brings stability and a long-term vision with the aim of …See details»
Debiopharm - Overview, News & Similar companies | ZoomInfo.com
May 29, 2024 Debiopharm contact info: Phone number: +41 213210111 Website: www.debiopharm.com What does Debiopharm do? Founded in 1979, Debiopharm is a family …See details»
The Swiss biotech shaking up the antibiotics model
Oct 15, 2020 Debiopharm spots promising research in its early stages, in-licenses or acquires it, develops the molecules, and then licenses it out to a larger pharmaceutical company to …See details»
Debiopharm Innovation Fund - Crunchbase
Debiopharm Innovation Fund invests in digital health companies that have an impact on cancer, infectious diseases, and drug development. We are looking for ambitious entrepreneurs …See details»
Debiopharm - Products, Competitors, Financials, Employees, …
Debiopharm to Showcase Research Results of Their First-in-class Anti-staphylococcal Program at IDWeek 2024 in Los Angeles. Oct 15, 2024. LAUSANNE, Switzerland--(BUSINESS WIRE)- …See details»
Debiopharm Innovation Fund
As Debiopharm’s strategic corporate fund, we not only invest but also provide strategic guidance to startups transforming Pharma R&D and cancer care. Access our launchpad towards …See details»
We develop for patients – Debiopharm – Clinical trials
Debiopharm's vision of healthcare is not limited to making new medicines available. We strongly believe that you can be an actor in your own medical care. The researcher. A researcher is a …See details»
Our Expertise - Debiopharm
Deep dive into our expertise. Antibody-Drug Conjugates (ADC) Discover Antibiotic-Resistant Infections (AMR) DiscoverSee details»
Corporate Responsibility - Debiopharm
We believe that all forms of diversity are a valuable source of creativity and innovation. Promoting equality in the workplace is part of our DNA and supported by longstanding policies to manage …See details»